Vasudha Bal

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
BACKGROUND Compliance, palatability, gastrointestinal (GI) symptom, and treatment satisfaction patient- and observer-reported outcome (PRO, ObsRO) measures were developed/modified for patients with transfusion-dependent anemias or myelodysplastic syndrome (MDS) requiring iron chelation therapy (ICT). METHODS This qualitative cross-sectional observational(More)
Chronic lymphocytic leukemia (CLL) is an incurable disease. Quality of life during treatment and periods of subsequent remission is therefore vital. Health-related quality of life (HRQoL) was compared in relapsed CLL during and after treatment with ofatumumab combined with fludarabine and cyclophosphamide versus fludarabine and cyclophosphamide alone. The(More)
patients presented an overall clinical improvement of ≥ 20%, ≥ 50% and ≥ 80%. These improvements were associated with a reduction of steroid use (75% of patients on steroids at belimumab-initiation decreased mean dose from 14.8 to 6.8mg/day; p< 0.001) and HRU between the pre/post index periods: emergency-room visits 1.65 to 0.41; p= 0.001; unscheduled(More)
BACKGROUND Health authorities and payers increasingly recognize the importance of patient perspectives and patient-reported outcomes (PROs) in health care decision making. However, given the broad variety of PRO endpoints included in clinical programs and variations in the timing of PRO data collection and country-specific needs, the role of PRO data in(More)
  • 1